Business Parks & Science Centres

 
 
 

Advertisement

Picture Berlin Partner HealthCapital Bionnale 2019 Germany May 600x94px
Collaboration › Details

Atlatl–Miltenyi Biotec: CliniMACSProdigy platform, 201903– collab co-founding of Atlatl-Macs Center for Gene + Cell Therapy in Shanghai

 

Period Period 2019-03-20
Organisations Partner, 1st Atlatl Innovation Cluster (AIC)
  Group Atlatl (Group)
  Partner, 2nd Atlatl-Macs Center for Gene and Cell Therapy (Shanghai)
  Group Miltenyi Biotec (Group)
Products Product CliniMACS Prodigy® platform
  Product 2 business park management / science park management
     

Atlatl Innovation Cluster. (3/20/19). "Press Release: Center for Gene and Cell Therapy Co-founded by Miltenyi and ATLATL in Shanghai". Shanghai.

To accelerate the development of cell and gene therapy, ATLATL Center and Miltenyi Biotec have cooperated to build ATLATL-MACS Center for Gene and Cell Therapy. Miltenyi is a global leader in the design, development, manufacturing, and integration of products that empower the advancement of biomedical research and enable cutting-edge cell and gene therapies. Miltenyi provides a robust innovative portfolio of cellular technologies used seamlessly in a variety of research, translational, and clinical applications.

ATLATL has the world’s largest shared Class-A level laboratory space, designed as a launchpad for high-potential life sciences. It offers fully permitted laboratories and office space for scientists and entrepreneurs. To meet the demands of growing research teams, ATLATL provides full service state-of-the-art facilities, the most advanced instruments, professional operations support, skilled laboratory personnel, on-site CROs, and the most creative Module research services, serving teams of various size who need to begin immediate laboratory operations. The Center is approximately 25,000 square feet, functions as a talent training center, expedites process development, and cell and gene therapy platforms. The center includes specialized laboratories for cell collection, separation, production, microscopic imaging, and storage and transportation.

In recent years, advances in gene editing technology and viral vectors, gene and cell therapy has developed from theory to reality with major breakthroughs, as a promising emerging sector in medicine. Companies engaged in this field are sought in capital markets, and a large number of companies have completed IPO listings, including Bluebird Bio, Celladon, Orchard, and Spark. Many gene and cell therapies have demonstrated impressive results in clinical trials and more treatments could be approved in coming years.

ATLATL and Miltenyi spent nearly one year on planning and construction, finally built the ATLATL-MACS Center in March 2019 with a specialized focus to remove hurdles encountered in current treatments. The Center offers a complete research and development platform and will actively train researchers, work with more R&D teams to conduct new process development and application discovery, establish complete standardized operating procedures, assist pharmaceutical companies conduct accurate disease diagnosis and efficacy evaluations, accelerating clinical transformation and commercialization of gene and cell therapy.

The ATLATL-MACS Center covers the biomedical industry chain and will gather a series of innovative teams, which have important strategic significance for the development of local life sciences. The center will provide services to biological companies through more than 10 million euro cutting-edge instruments and expert team. Miltenyi’s CliniMACSProdigy is the unique automated CAR-T preparation instrument, greatly speeding up the cell therapy and development in clinical applications. The Center will lower the gene and cell therapy industry innovation threshold locally and globally.

Miltenyi Biotec has previously collaborated with many giant pharmaceuticals, such as GlaxoSmithKline (GSK) on the "industrialization" of cell and gene therapy. Differently, the cooperation between Miltenyi and ATLATL is an open platform to biotech companies. The center will help biopharmaceutical companies and scientific research institutions integrate R&D, training, commercialization. It will greatly reduce the initial cost in research and development and help companies accelerate the clinical transformation and commercialization of cell and gene therapy to benefit more patients.

{ATLATL Center is a component of ATLATL Innovation Cluster (AIC), which is an ecosystem with educational and research centers, on-site CROs, entrepreneurship, venture capital, and life sciences companies. AIC strives to increase research density and accelerate research commercialization. Innovative teams can jumpstart with turnkey solutions, leverage resources more efficiently, and reach milestones faster than ever.}


Contacts

ATLATL
Amanda Huo
info@atlatl.center
+86 21-58332229

   
Record changed: 2019-03-22

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

More documents for Atlatl (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px




» top